RATIONALE: The endogenous opioid system has been implicated in substance abuse and response to pharmacotherapies for nicotine and alcohol addiction. We examined (1) the association of the functional OPRM1 A118G variant with the relative reinforcing value of nicotine and (2) the main and interacting effects of the mu-opioid receptor antagonist naltrexone on nicotine reinforcement. METHODS: In a within-subject, double-blind human laboratory study, 30 smokers of each OPRM1 genotype (A/A vs. A/G or G/G) participated in two experimental sessions following 4 days of orally administered naltrexone 50 mg or placebo. Participants completed a validated assessment of the relative reinforcing value of nicotine. This cigarette choice paradigm assesses self-administration of 0.6 mg nicotine vs. 0.05 mg (denicotinized) cigarettes after a brief period of nicotine abstinence. RESULTS: The relative reinforcing value of nicotine (number of nicotine cigarette puffs) was predicted by a significant OPRM1 by gender interaction. Among women, the low-activity G allele (A/G and G/G) was associated with a reduced reinforcing value of nicotine; among male smokers, there was no association with genotype. Smokers carrying a G allele were also significantly less likely to differentiate the nicotine vs. denicotinized cigarettes by subjective ratings of satisfaction and strength. No evidence for an effect of naltrexone on nicotine reinforcement was found in the overall sample or in the genotype or gender subgroups. CONCLUSIONS: This study provides initial evidence for an association of the OPRM1 A118G variant with nicotine reinforcement in women.
RCT Entities:
RATIONALE: The endogenous opioid system has been implicated in substance abuse and response to pharmacotherapies for nicotine and alcohol addiction. We examined (1) the association of the functional OPRM1A118G variant with the relative reinforcing value of nicotine and (2) the main and interacting effects of the mu-opioid receptor antagonist naltrexone on nicotine reinforcement. METHODS: In a within-subject, double-blind human laboratory study, 30 smokers of each OPRM1 genotype (A/A vs. A/G or G/G) participated in two experimental sessions following 4 days of orally administered naltrexone 50 mg or placebo. Participants completed a validated assessment of the relative reinforcing value of nicotine. This cigarette choice paradigm assesses self-administration of 0.6 mg nicotine vs. 0.05 mg (denicotinized) cigarettes after a brief period of nicotine abstinence. RESULTS: The relative reinforcing value of nicotine (number of nicotine cigarette puffs) was predicted by a significant OPRM1 by gender interaction. Among women, the low-activity G allele (A/G and G/G) was associated with a reduced reinforcing value of nicotine; among male smokers, there was no association with genotype. Smokers carrying a G allele were also significantly less likely to differentiate the nicotine vs. denicotinized cigarettes by subjective ratings of satisfaction and strength. No evidence for an effect of naltrexone on nicotine reinforcement was found in the overall sample or in the genotype or gender subgroups. CONCLUSIONS: This study provides initial evidence for an association of the OPRM1A118G variant with nicotine reinforcement in women.
Authors: Margaret Rukstalis; Christopher Jepson; Andrew Strasser; Kevin G Lynch; Kenneth Perkins; Freda Patterson; Caryn Lerman Journal: Psychopharmacology (Berl) Date: 2005-01-29 Impact factor: 4.530
Authors: E Sarton; E Olofsen; R Romberg; J den Hartigh; B Kest; D Nieuwenhuijs; A Burm; L Teppema; A Dahan Journal: Anesthesiology Date: 2000-11 Impact factor: 7.892
Authors: K E Hutchison; P M Monti; D J Rohsenow; R M Swift; S M Colby; M Gnys; R S Niaura; A D Sirota Journal: Psychopharmacology (Berl) Date: 1999-02 Impact factor: 4.530
Authors: Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller Journal: Tob Control Date: 2010-10 Impact factor: 7.552
Authors: Jacqueline M Vink; August B Smit; Eco J C de Geus; Patrick Sullivan; Gonneke Willemsen; Jouke-Jan Hottenga; Johannes H Smit; Witte J Hoogendijk; Frans G Zitman; Leena Peltonen; Jaakko Kaprio; Nancy L Pedersen; Patrik K Magnusson; Tim D Spector; Kirsten Ohm Kyvik; Katherine I Morley; Andrew C Heath; Nicholas G Martin; Rudi G J Westendorp; P Eline Slagboom; Henning Tiemeier; Albert Hofman; Andre G Uitterlinden; Yurii S Aulchenko; Najaf Amin; Cornelia van Duijn; Brenda W Penninx; Dorret I Boomsma Journal: Am J Hum Genet Date: 2009-03-05 Impact factor: 11.025
Authors: Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Xiaoqiang Xu; J James Frost; Dean F Wong; Mary E McCaul Journal: Addict Biol Date: 2012-12-18 Impact factor: 4.280
Authors: Jill Hardin; Yungang He; Harold S Javitz; Jennifer Wessel; Ruth E Krasnow; Elizabeth Tildesley; Hyman Hops; Gary E Swan; Andrew W Bergen Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254